Catalyst
Slingshot members are tracking this event:
Phase 2 pegilodecakin (PEG-rhuIL-10) in combination with PD-1 antibody (pembrolizumab or nivolumab) in second-line NSCLC
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARMO |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 02, 2018
Occurred Source:
http://abstracts.asco.org/214/AbstView_214_226303.html
Related Projects
- Discussing the NSCLC landscape after KEYNOTE-189 data, specifically PD-1 combo programs MRK, ARMO, NKTR Executed On: Apr 30, 2018 at 10:00 AM EDT
Related Keywords
Interleukin-10, Cytokine, Nsclc, Cancer Immunotherapy, Pd-1 Inhibitor, Combination Therapy, Lung Cancer, Non-small Cell Lung Cancer
